AGIO Agios Pharmaceuticals, Inc.
Price Chart
Executive Summary
Agios Pharmaceuticals licensed exclusive global rights to cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia (ITP), from Oscotec for $25M upfront plus up to $140M in development/regulatory milestones and tiered royalties. The Phase 2 trial missed its primary endpoint but showed durable platelet responses on secondary endpoints; Agios plans to advance to Phase 3 in H1 2028. The deal diversifies Agios' rare hematology portfolio into ITP, a market with up to $1B peak U.S. sales potential, but the asset carries clinical risk given the primary endpoint miss.
Key Financial Metrics
Actionable Insight
The deal adds a late-stage pipeline asset with a clear path to Phase 3, but the primary endpoint miss in Phase 2 introduces clinical risk. Monitor for Phase 3 trial design details and enrollment updates in H1 2028. The $25M upfront is manageable for Agios ($1.7B market cap) and does not alter 2026 expense guidance materially. Near-term stock reaction likely hinges on investor perception of the Phase 2 data's regulatory viability versus the $1B peak sales narrative.
Key Facts
- Agios pays $25M upfront for exclusive global rights to cevidoplenib, a next-generation oral SYK inhibitor for ITP.
- Oscotec eligible for up to $140M in development/regulatory milestones across three indications plus commercial milestones and high-single-digit to mid-teen royalties.
- Phase 2 trial (NCT04056195) missed primary endpoint (platelet response) but showed durable clinically meaningful responses on secondary endpoints.
- Agios expects to start Phase 3 in H1 2028 after completing CMC development work.
- ITP affects ~200,000 globally, ~90,000 adults in U.S.; ~50,000 have chronic ITP requiring treatment.
- Agios maintains 2026 operating expense guidance approximately flat vs 2025, excluding the $25M upfront payment.
- Cevidoplenib has FDA orphan drug designation for ITP.
Financial Impact
$25M upfront payment; up to $140M in development/regulatory milestones; up to $1B peak U.S. sales potential per Agios; royalties high-single-digit to mid-teen on net sales.
Risk Factors
- Phase 2 primary endpoint miss raises regulatory risk; FDA may require additional data before Phase 3.
- Cevidoplenib faces competition from existing ITP therapies (TPO-RA, rituximab, fostamatinib).
- Development and commercialization costs could exceed expectations, pressuring cash runway.
- Oscotec retains option for South Korea rights post-Phase 3, limiting global upside.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304100 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
4d ago
|
Press Release
| — | awaiting T+5 | — | — |
|
May 29, 2026
7d ago
|
Press Release
| $29.40 $27.68 | ▲ +5.85% | ▲ +5.56% | $28.22 (+4.01%) |
|
Apr 29, 2026
5w ago
|
8-K
| — | awaiting T+5 | — | — |
|
Apr 29, 2026
5w ago
|
Press Release
| — | awaiting T+5 | — | — |
|
Apr 24, 2026
5w ago
|
DEFA14A
| $24.43 $27.56 | ▲ +12.81% | ▲ +12.41% | $28.22 (+15.51%) |
|
Apr 6, 2026
8w ago
|
Press Release
| $34.80 $33.15 | ▼ −4.74% | ▼ −8.88% | $28.22 (−18.91%) |
|
Mar 3, 2026
13w ago
|
Insider Cluster
| $28.48 $28.26 | ▼ −0.77% | ▼ −0.29% | $28.22 (−0.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access